3309.HK

The latest: C-Mer Eye Care Holdings Ltd. (3309.HK) announced on Thursday it agreed to purchase 55% of lens distributor Apollo Lens Co. Ltd. for 50.49 million yuan ($71.2 million).

Looking up: The acquisition will allow Hong Kong-based C-Mer to immediately establish its presence in the prescription lens development and distribution market in mainland China, drawing on Apollo’s large operation there.

Take Note: C-Mer plans to pay the seller using a bond certificate with principal amount of 50.49 million yuan for three years and an interest rate of 2% per annum.

Digging Deeper: Founded in 2012 by renowned Hong Kong ophthalmologist Dennis Lam, C-Mer Eye Care is a leading eye care chain in China’s Greater Bay Area centered on the Pearl Delta in Guangdong province. It operated nine eye hospitals covering five key cities in the region as of the end of last year. While it lost money last year, the company’s management noted that its operations in mainland China improved significantly in the first quarter of this year after China relaxed its Covid controls last December. It said some operations have even returned to pre-pandemic levels.

Market Reaction: C-Mer shares rose on Friday, closing up 2.1% at HK$3.99 by the midday break. The stock now trades in the middle of its 52-week range.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…